Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Moodys
AstraZeneca
Dow
Colorcon

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01497899 ↗ Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 2 2011-12-28 The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗ D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults Completed Gilead Sciences Phase 2 2012-04-01 This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗ Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 3 2012-12-26 The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
NCT01797445 ↗ Study to Evaluate the Safety and Efficacy of E/C/F/TAF Versus E/C/F/TDF in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 3 2013-03-12 The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) in HIV-1 positive, antiretroviral treatment-naive adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Condition Name

Condition Name for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention Trials
HIV-1 Infection 9
Hiv 8
HIV Infections 5
HIV-1-infection 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Intervention Trials
HIV Infections 11
Acquired Immunodeficiency Syndrome 7
Immunologic Deficiency Syndromes 5
Hepatitis B 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Trials by Country

Trials by Country for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location Trials
United States 292
Canada 36
United Kingdom 17
France 15
Spain 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Location Trials
California 18
Florida 17
Georgia 15
Texas 14
North Carolina 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Clinical Trial Phase

Clinical Trial Phase for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase Trials
Phase 4 5
Phase 3 17
Phase 2 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Clinical Trial Phase Trials
Completed 22
Recruiting 5
Active, not recruiting 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Sponsor Name

Sponsor Name for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor Trials
Gilead Sciences 21
National Institute of Allergy and Infectious Diseases (NIAID) 3
University of California, San Diego 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Sponsor Trials
Other 26
Industry 24
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.